Nine list­ings and $3.8B lat­er, HKEX cel­e­brates one-year biotech an­niver­sary with $194M CRO IPO

So how is Hong Kong stock ex­change’s biotech board do­ing one year af­ter reg­u­la­tors opened up the list­ing regime to pre-rev­enue com­pa­nies in the field?

De­pends on how you look at it.

While on­ly nine biotech com­pa­nies — in­clud­ing one CRO gi­ant — have joined the HKEX this way in the past year, col­lec­tive­ly they have raised $3.8 bil­lion. By IPO pro­ceeds, that makes Hong Kong the sec­ond largest pub­lic biotech hub world­wide af­ter the leader Nas­daq, ac­cord­ing to Re­fini­tiv da­ta cit­ed by the lo­cal South Chi­na Morn­ing Post.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER